Skip to main content

Sionna Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 2, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 2, 2026

SION$3.57+8.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SIONNA THERAPEUTICS, INC.
By:/s/Michael Cloonan
Name:Michael Cloonan, M.B.A.
Title:President and Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

Each individual whose signature appears below hereby constitutes and appoints Michael Cloonan, M.B.A., and Elena Ridloff, C.F.A., as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report and Power of Attorney has been signed by the following person in the capacities and on the date indicated.

SignatureTitleDate
/s/ Michael CloonanPresident, Chief Executive Officer and Director (Principal Executive Officer)March 2, 2026
Michael Cloonan, M.B.A.
/s/ Elena RidloffChief Financial Officer (Principal Financial Officer and Principal Accounting Officer)March 2, 2026
Elena Ridloff, C.F.A.
/s/ Paul ClancyChair of the Board of DirectorsMarch 2, 2026
Paul Clancy, M.B.A.
/s/ Bruce BoothDirectorMarch 2, 2026
Bruce Booth, D.Phil.
/s/ H. Edward Fleming, Jr.DirectorMarch 2, 2026
H. Edward Fleming, Jr., M.D.
/s/ Lucian IancoviciDirectorMarch 2, 2026
Lucian Iancovici, M.D.
/s/ Joshua ResnickDirectorMarch 2, 2026
Joshua Resnick, M.D., M.B.A.
SignatureTitleDate
/s/ Marcella K. RuddyDirectorMarch 2, 2026
Marcella K. Ruddy, M.D.
/s/ Laurie StelzerDirectorMarch 2, 2026
Laurie Stelzer, M.B.A.
/s/ Peter A. ThompsonDirectorMarch 2, 2026
Peter A. Thompson, M.D.
/s/ Joanne VineyDirectorMarch 2, 2026
Joanne Viney, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.